PD-1 (D4W2J) – 148Nd

Catalog: 714801                                            Clone: D4W2J                                            Isotype: Rabbit IgG
Reactivity: Human*
Storage: Supplied in antibody stabilizer with 0.05% sodium azide. Store a 4°C

IHC: PD-1 staining of FFPE human tonsil

MIBI: PD-1 staining (cyan) of FFPE human tonsil, counterstained with dsDNA (magenta)

IHC: PD-1 staining of FFPE human liver

MIBI: PD-1 staining (cyan) of FFPE human liver, counterstained with dsDNA (magenta)

Background: PD-1 (programmed cell death protein 1, CD279) is expressed on activated T cells and binds to PD-L1 and PD-L2 to inhibit T cell activation through recruitment of phosphatases that attenuate TCR signaling. The interaction between PD-1 and PD-L1 supports tolerance to self-antigens and contributes to the healthy down-regulation of immune activation following viral clearance. In cancer the PD-1/PD-L1 interaction is exploited by tumor cells to dampen an immune response from tumor-infiltrating lymphocytes and as such these immune checkpoint molecules are being actively targeted by immuno-oncology therapies.

Validation: Each lot of conjugated antibody is quality control tested by MIBIscope™ analysis of stained tissue microarray using the appropriate positive and negative tissue field of views and are pathologist verified.

Recommended Usage: 1 uL per 100 uL staining volume using the MIBI™ Staining Protocol.
For optimal results, antibody should be titrated for each desired application.  Suggested starting range is 1:100.


  • Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response
    Biomarkers and Combinations. Science translational medicine. 2016; 8(328):328rv4.

* Conjugate tested on human tissue.

Contact Us

We are glad that you prefer to contact us. Please fill our short form and one of our friendly team members will contact you back.

Immuno-oncology/CancerNeuroscienceInfectious DiseaseImmunologyStem CellOther

Contact Us

We are using cookies on our website

Please confirm, if you accept our tracking cookies. You can also decline the tracking, so you can continue to visit our website without any data sent to third party services.